Expand all sections

Atezolizumab

Tecentriq

Extended indication

In combination with cabozantinib patients with mCRPC previously treated with novel hormonal therapy

Therapeutic value

No estimate possible yet
Registration phase

Clinical trials

Product

Active substance

Atezolizumab
Domain

Oncology
Reason of inclusion

Indication extension
Main indication

Prostate cancer
Extended indication

In combination with cabozantinib patients with mCRPC previously treated with novel hormonal therapy (NHT)
Proprietary name

Tecentriq
Manufacturer

Roche
Portfolio holder

Roche
Mechanism of action

PD-1 / PD-L1 inhibitor
Route of administration

Intravenous
Therapeutical formulation

Concentrate for solution for infusion
Budgetting framework

Intermural (MSZ)

Registration

Registration route

Centralised (EMA)
Type of trajectory

Normal trajectory
ATMP

No
Submission date

October 2023
Expected Registration

June 2024
Orphan drug

No
Registration phase

Clinical trials

Therapeutic value

Therapeutic value

No estimate possible yet
Frequency of administration

1 times every 3 weeks
Dosage per administration

1200 mg
References 
NCT04446117

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

Cost

40,000.00 - 60,000.00
Additional remarks 
Op basis van lijstprijs per vial (1.200mg atezolizumab) van €4.145. Kosten per patiënt per jaar zijn een inschatting in verband met onbekende behandelduur. Voor alle indicaties van atezolizumab geldt een financieel arrangement die is voortgekomen uit de onderhandelingen in de sluis (lopend tot en met 31 december 2023).

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension

Yes
Indication extensions

Verschillende indicaties
References 
Product Development Portfolio

Other information

There is currently no futher information available.